Dateline City:
KENILWORTH, N.J. & HOUSTON
Clinical Trials to Evaluate Mercks KEYTRUDA (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types
KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
The University of Texas MD Anderson Cancer Center today announced that
they have entered into a strategic clinical research collaboration to
evaluate Mercks anti-PD-1 therapy, KEYTRUDA
(pembrolizumab), in combination with other treatments, such as
chemotherapy, radiation therapy and/or novel antitumor medicines.
Language:
English
Contact:
Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orMD Anderson Media Relations:Ron Gilmore, 713-745-1898Rlgilmore1@mdanderson.org
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more